Ramixotidine (also known as CM 57755 ) is a nicotinamide 1-oxide derivative patented by Sanofi as a gastric antisecretory agent. Ramixotidine is competitive histamine H2-receptor antagonist, that inhibits histamine-induced gastric acid secretion. In preclinical studies, Ramixotidine caused inhibition of dimaprit- or pentagastrin-induced secretion. Acid secretion stimulated by a meat meal was significantly reduced by Ramixotidine Ramixotidine appears to be an inhibitor of gastric acid secretion induced by different stimulants in dogs with a potency comparable to cimetidine. Unfortunately, in clinical trials, Ramixotidine failed to demonstrate efficacy and further development was discontinued.